HCA Healthcare
HCA
$425.49
-0.34%
HCA Healthcare, Inc. is the largest for-profit hospital operator in the United States, running 190 acute-care hospitals and over 2,500 outpatient facilities across 19 states, with a small international foothold in the United Kingdom. Its scale, dense urban-market clustering, and vertically integrated outpatient network make it the dominant platform in the medical-care-facilities industry, distinct from smaller regional peers and non-profit systems. The current investor narrative centers on a tug-of-war between resilient core volume growth — Q1 2026 revenue rose 4.3% year over year to $19.1 billion — and intensifying reimbursement pressure from unfavorable payer mix, a theme echoed across the sector after Tenet Healthcare's soft Q1 revenue print. Bulls point to an aging U.S. population, disciplined capital returns, and a forward P/E near 13x as evidence of a durable long-term compounder; bears highlight policy risk, elevated leverage, and a stock that has materially lagged the S&P 500 over the past year.…
HCA
HCA Healthcare
$425.49
Related headlines
Investment Opinion: Should I buy HCA Today?
The synthesized recommendation is Hold, with a bias toward accumulating on weakness. The core thesis is that HCA's 13.31x forward P/E and 0.572 PEG ratio already discount a meaningful portion of reimbursement risk, but the absence of a near-term catalyst and the recent margin compression justify waiting for clearer signs of stabilization. The analyst consensus rating of 'buy' with a mean of 2.0 and an average target price of $451.48 implies only 5.7% upside, which is not compelling enough to chase the stock at $426.94, especially with a beta of 1.109 and a wide target range of $380 to $579.
Supporting evidence for a Hold includes: (1) valuation is undemanding at 13.31x forward earnings and 10.05x EV/EBITDA, well below the broader healthcare sector's low-to-mid 20s P/E; (2) revenue growth of 4.3% year over year in Q1 2026 is steady but decelerating from 5.1% in Q4 2025; (3) profitability is compressing, with operating margin falling to 14.98% from 16.29% sequentially and net margin at 8.48%; (4) free cash flow of $7.93 billion is robust and covers buybacks and capex, but negative equity and a 0.83 current ratio limit flexibility; and (5) the implied upside to the average analyst target is only 5.7%, while the downside to the low target is 11.0%. The stock's 1.42x PS ratio is near the low end of its historical range, suggesting the market is pricing in a recession-like scenario for hospital operators.
The biggest risks that could invalidate the Hold thesis are: (1) a further deterioration in payer mix that pushes operating margin below 14%, which would likely trigger analyst downgrades and a retest of the $354 low; (2) a policy surprise, such as Medicare rate cuts or a Medicaid expansion rollback, that reduces revenue per patient; and (3) a recession that increases unemployment and shifts more patients to government payers. The rating would upgrade to Buy if HCA's operating margin stabilizes above 15% for two consecutive quarters and the forward P/E remains below 14x, or if the stock drops below $380 (the analyst low target) without a fundamental deterioration. It would downgrade to Sell if operating margin falls below 13% or if revenue growth decelerates below 3%. Relative to its own history and peers, HCA appears fairly valued to slightly undervalued, but the lack of a near-term catalyst and the wide analyst dispersion argue for patience rather than aggressive buying.
Sign up to view all
HCA 12-Month Price Forecast
HCA presents a balanced risk/reward at the current price of $426.94. The valuation is undemanding at 13.31x forward earnings and 10.05x EV/EBITDA, and the 0.572 PEG ratio suggests the stock is cheap relative to its growth rate. However, the recent margin compression and negative equity position are concerning, and the analyst consensus target offers limited upside. The stock's beta of 1.109 and max drawdown of -33.72% indicate that downside risk is meaningful if policy headwinds intensify. I would upgrade to bullish if HCA demonstrates two consecutive quarters of stable or expanding operating margins above 15%, and I would downgrade to bearish if operating margin falls below 14% or if revenue growth decelerates below 3%. The most likely scenario is a range-bound stock over the next 12 months, with the base case target of $430-$470.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on HCA Healthcare's 12-month outlook, with a consensus price target around $451.48 and implied upside of +6.1% versus the current price.
Average Target
$451.48
0 analysts
Implied Upside
+6.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$380 - $579
Analyst target range
Coverage is robust with 21 analysts, and the consensus recommendation is "buy" with a recommendation mean of 2.0. The average target price of $451.48 implies roughly 5.7% upside from the current price of $426.94, a modest but positive signal. The consensus leans moderately bullish, supported by the estimated EPS average of $44.81 and estimated revenue average of $96.29 billion, but the upside to the average target is thin enough that the stock is not priced for aggressive outperformance. The target range spans from a low of $380 to a high of $579, a spread of $199, or roughly 44% of the average target — a wide dispersion that signals genuine disagreement about the trajectory of reimbursement rates and volume growth. The high target of $579 implies multiple expansion toward 13x forward earnings on the high end of EPS estimates, or a re-rating if policy headwinds ease; the low target of $380 prices in margin compression and a retest of the 52-week low. Recent institutional actions show a mix of holds and buys: Barclays downgraded to Equal Weight from Overweight in July 2026, while Cantor Fitzgerald, TD Cowen, Truist, KeyBanc, Stephens, and Oppenheimer maintained bullish ratings in April and June. The lack of recent upgrades and the presence of a downgrade suggest analysts are in a wait-and-see mode, and the wide target spread means investors should expect continued volatility until the policy and payer-mix picture clarifies.
Bulls vs Bears: HCA Investment Factors
The bear case currently has stronger near-term evidence: HCA's operating margin compressed 131 basis points sequentially, net income fell 13.8% quarter over quarter, and the stock has underperformed the S&P 500 by over 10 percentage points in the past year. However, the bull case rests on a compelling valuation floor — a 13.31x forward P/E, a 0.572 PEG ratio, and $7.93 billion in trailing free cash flow — that may already price in much of the reimbursement pessimism. The single most important tension is whether the payer mix deterioration is a cyclical headwind that stabilizes in 2026 or a structural shift that permanently lowers margins; if Q2 2026 margins stabilize above 15%, the stock could re-rate toward the $451 average target, but a further decline below 14% would likely retest the $354 low.
Bullish
- Deep Value on Forward Earnings: HCA trades at a forward P/E of 13.31x, an 18.4% discount to its trailing P/E of 16.31x, implying the market expects meaningful EPS growth. The PEG ratio of 0.572 suggests the stock is undervalued relative to its growth rate, and the 25-30% discount to the broader healthcare sector's low-to-mid 20s P/E provides a margin of safety.
- Robust Cash Generation Funds Buybacks: HCA generated $7.93 billion in trailing free cash flow and $2.01 billion in Q1 2026 operating cash flow, comfortably covering $1.12 billion of quarterly capex and $1.57 billion of buybacks. This self-funding capacity supports EPS accretion and shareholder returns even without multiple expansion.
- Improving Relative Momentum: Over the past three months, HCA has gained 10.27% versus the S&P 500's 3.04%, producing relative strength of +7.23%. The one-month relative strength of +4.04% also outpaced the market, suggesting the stock is in the early stages of a bottoming process after a brutal -33.72% max drawdown.
- Analyst Consensus Buy with Upside: 21 analysts rate HCA a 'buy' with a mean recommendation of 2.0 and an average target price of $451.48, implying 5.7% upside from the current $426.94. The high target of $579 suggests 35.6% upside if policy headwinds ease and margins recover.
Bearish
- Margin Compression Accelerating: Q1 2026 operating margin fell to 14.98% from 16.29% in Q4 2025, and EBITDA margin compressed to 19.89% from 21.29%. Net income declined to $1.62 billion from $1.88 billion sequentially, showing that cost inflation and unfavorable payer mix are eroding profitability.
- Negative Equity and High Leverage: HCA's debt-to-equity ratio is -8.33 due to negative shareholders' equity, and its debt ratio stands at 81.1%. The current ratio of 0.83 signals tight near-term liquidity, limiting financial flexibility if reimbursement pressures intensify.
- Reimbursement and Payer Mix Headwinds: Government payers (Medicare, Medicaid, and managed versions) account for roughly $8.95 billion of quarterly revenue, and the shift toward lower-reimbursing government plans pressures per-patient economics. Tenet Healthcare's soft Q1 revenue print due to unfavorable admissions mix highlights this as an industry-wide challenge.
- Significant Underperformance vs. Market: HCA has lagged the S&P 500 by 10.24 percentage points over the past year and by 21.32 percentage points year to date. The six-month relative strength of -35.29% underscores how severely the stock has de-rated relative to the broader market.
HCA Technical Analysis
HCA is in a broad downtrend punctuated by a sharp but incomplete recovery. The stock is up 5.98% over the past year and 5.73% year to date, but sits 23.3% below its 52-week high of $556.52 and 20.6% above its 52-week low of $353.99, placing it at roughly 35% of its 52-week range — closer to the floor than the ceiling. That positioning reflects a market that has de-rated the name rather than abandoned it, with the current price of $426.94 recovering from a brutal drawdown that reached -33.72% at its worst. Momentum is now improving at the margin: the stock is up 2.98% over the past month and 10.27% over three months, both outpacing the S&P 500's -1.06% and +3.04% respective returns, producing relative strength of +4.04% and +7.23%. However, the six-month change of -19.89% and year-to-date decline of -9.24% show the recovery is early-stage, and the 1-year relative strength of -10.24% confirms HCA has been a laggard. The divergence between strong 3-month momentum and negative 6-month performance suggests a bottoming process rather than a confirmed trend reversal, and the 5.19 short ratio indicates bears have not fully capitulated. Key resistance sits at the 52-week high of $556.52, while support is anchored at the 52-week low of $353.99; a breakout above $450-$460 would signal the downtrend is broken, whereas a breakdown below $400 would retest the lows. With a beta of 1.109, HCA is roughly 11% more volatile than the market, meaning position sizing should account for amplified moves in both directions, and the -33.72% max drawdown underscores the downside risk in a policy-driven selloff.
Beta
1.11
1.11x market volatility
Max Drawdown
-33.7%
Largest decline past year
52-Week Range
$354-$557
Price range past year
Annual Return
+5.0%
Cumulative gain past year
| Period | HCA Return | S&P 500 |
|---|---|---|
| 1m | +5.1% | -2.0% |
| 3m | +7.2% | +1.4% |
| 6m | -15.2% | +15.0% |
| 1y | +5.0% | +15.7% |
| ytd | -9.5% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HCA Fundamental Analysis
Revenue growth is steady but decelerating. Q1 2026 revenue of $19.11 billion grew 4.3% year over year, a slowdown from the 5.1% pace implied by Q4 2025's $19.51 billion versus Q4 2024's $18.29 billion, and the sequential trend shows Q1 2026 revenue slightly below Q4 2025. The payer mix is the key swing factor: managed care and other insurers contribute $9.08 billion, managed Medicare $3.51 billion, Medicare $3.06 billion, Medicaid $1.44 billion, and managed Medicaid $939 million, with the shift toward government payers pressuring per-patient economics. The 4.3% growth rate is respectable for a mature hospital operator but leaves little cushion if reimbursement rates tighten further. Profitability remains solid but is compressing at the margin. Q1 2026 net income of $1.62 billion on a 8.48% net margin was down from Q4 2025's $1.88 billion and 9.62% margin, while the quarterly gross margin of 14.98% (as reported) is well below the 41.5% gross margin shown in the valuation data — a discrepancy that reflects differing cost classifications, but the directional signal is clear: operating margin slipped to 14.98% in Q1 2026 from 16.29% in Q4 2025. EBITDA fell to $3.80 billion from $4.16 billion sequentially, and the EBITDA margin compressed to 19.89% from 21.29%, suggesting cost inflation and payer mix are eroding profitability. The balance sheet carries meaningful leverage: debt-to-equity is deeply negative at -8.33 due to negative shareholders' equity, the current ratio of 0.83 signals tight near-term liquidity, and the debt ratio of 81.1% is elevated. Still, the company generates substantial cash — $7.93 billion in trailing free cash flow and $2.01 billion in Q1 2026 operating cash flow — which comfortably covers $1.12 billion of quarterly capex and $1.57 billion of buybacks. The negative equity position is a function of aggressive share repurchases and accumulated goodwill rather than operational distress, but it does limit financial flexibility if conditions deteriorate.
Quarterly Revenue
$19.1B
2026-03
Revenue YoY Growth
+4.3%
YoY Comparison
Gross Margin
15.0%
Latest Quarter
Free Cash Flow
$7.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HCA Overvalued?
Because HCA is profitable — Q1 2026 net income of $1.62 billion — the P/E ratio is the appropriate primary metric. The trailing P/E of 16.31x compares to a forward P/E of 13.31x, a 18.4% discount that implies the market expects meaningful earnings growth over the next twelve months, consistent with the consensus EPS estimate of $44.81. The PEG ratio of 0.572 suggests the stock is cheap relative to its growth rate, though the reliability of that signal depends on the durability of the growth forecast. On a price-to-sales basis, HCA trades at 1.42x, and its EV/EBITDA of 10.05x is the most relevant cross-check for a capital-intensive hospital operator. Relative to the broader healthcare sector, HCA's 16.31x trailing P/E is at a discount to the S&P 500 healthcare average, which typically runs in the low-to-mid 20s, implying a roughly 25-30% discount. That discount is partly justified by HCA's negative book value, elevated leverage, and exposure to government reimbursement risk, but it also reflects a market that is pricing in policy headwinds that may prove less severe than feared. The forward P/E of 13.31x is particularly notable for a company with HCA's scale and cash generation, and the 0.63% dividend yield, while modest, is well covered with a payout ratio of just 10.0%. Historically, HCA's P/E has ranged from roughly 8x to 20x over the past five years, with the current 16.31x sitting in the middle of that band. The stock's PS ratio of 1.42x is near the low end of its historical range — it traded above 5x in 2021-2022 — reflecting both the de-rating and the earnings recovery. The current valuation does not scream deep value, but it is far from stretched, and the gap between trailing and forward multiples suggests the market is pricing in a normalization of earnings rather than a structural decline.
PE
16.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 8x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.1x
Enterprise Value Multiple
Investment Risk Disclosure
HCA's financial risk profile is dominated by its highly leveraged balance sheet and negative equity. The debt-to-equity ratio of -8.33 reflects negative shareholders' equity, a byproduct of aggressive share repurchases and accumulated goodwill rather than operational distress, but it nonetheless limits financial flexibility. The current ratio of 0.83 indicates that current liabilities exceed current assets, creating near-term liquidity tightness, and the debt ratio of 81.1% is elevated for a capital-intensive hospital operator. While trailing free cash flow of $7.93 billion comfortably covers $1.12 billion of quarterly capex and $1.57 billion of buybacks, any deterioration in operating cash flow — say, from a reimbursement cut — would force HCA to choose between cutting buybacks, reducing capex, or increasing debt. Additionally, the sequential decline in Q1 2026 net income to $1.62 billion from $1.88 billion and the 131 basis point drop in operating margin to 14.98% show that profitability is already under pressure, leaving little cushion if cost inflation persists.
Market and competitive risks are significant given HCA's premium valuation relative to its own history and the sector. The stock trades at a trailing P/E of 16.31x, which is in the middle of its five-year range of 8x to 20x, but the forward P/E of 13.31x implies the market expects earnings growth that may not materialize if reimbursement headwinds worsen. The beta of 1.109 means HCA is roughly 11% more volatile than the market, so a broad market selloff would amplify losses. Competitive risks include the rise of outpatient surgery centers and telehealth, which could erode HCA's inpatient volumes, though its 2,500+ outpatient facilities provide some offset. Regulatory risk is acute: any expansion of Medicare for All, cuts to Medicaid disproportionate share hospital payments, or changes to the 340B drug discount program could directly hit margins. Recent news that Tenet Healthcare blamed admissions mix for soft Q1 sales underscores that payer mix is an industry-wide issue, not just an HCA-specific problem, but it also means peers are competing for the same favorable commercial volumes.
The worst-case scenario for HCA would be a combination of policy-driven reimbursement cuts and a recession that increases unemployment and shifts more patients to Medicaid or uninsured status. In that scenario, operating margins could fall below 13%, net income could drop toward $5 billion annually, and the stock could retest its 52-week low of $353.99, representing a 17.1% decline from the current price of $426.94. If the analyst low target of $380 is hit, that would be an 11.0% loss, but a more severe outcome — such as a surprise Medicare rate cut — could push the stock toward $350, a 18.0% decline. The historical max drawdown of -33.72% shows that HCA is capable of losing a third of its value in a policy-driven selloff, and with a short ratio of 5.19, bears have not yet capitulated, meaning further downside could be amplified by short selling.
FAQ
The most severe risk is reimbursement pressure: government payers account for roughly $8.95 billion of quarterly revenue, and any cuts to Medicare or Medicaid rates would directly hit margins. Second is financial leverage: the debt-to-equity ratio is -8.33 due to negative equity, and the current ratio of 0.83 indicates tight liquidity, limiting flexibility in a downturn. Third is margin compression: operating margin fell to 14.98% in Q1 2026 from 16.29% in Q4 2025, and further declines could trigger analyst downgrades. Fourth is market risk: with a beta of 1.109, HCA is more volatile than the market, and the historical max drawdown of -33.72% shows the stock can lose a third of its value in a policy-driven selloff. Finally, competitive risks from outpatient surgery centers and telehealth could erode inpatient volumes over time.
Our 12-month forecast assigns a 55% probability to the base case, with a target range of $430-$470, assuming revenue grows 4-5% and operating margin stabilizes around 15%. The bull case (25% probability) targets $500-$579, driven by margin recovery and multiple expansion toward 14-15x forward earnings. The bear case (20% probability) targets $354-$380, reflecting policy-driven reimbursement cuts and a recession that pushes operating margin below 13%. The most likely scenario is the base case, where HCA trades in a range and meets consensus EPS of $44.81. The key assumption is that payer mix does not deteriorate further and that no adverse policy changes occur. If Q2 2026 earnings show margin stabilization, the stock could move toward the upper end of the base case.
HCA appears fairly valued to slightly undervalued relative to its history and peers. The trailing P/E of 16.31x is in the middle of its five-year range of 8x to 20x, while the forward P/E of 13.31x is near the low end. The PS ratio of 1.42x is also near historical lows, compared to above 5x in 2021-2022. Relative to the broader healthcare sector, which trades at a low-to-mid 20s P/E, HCA is at a 25-30% discount. However, this discount is partly justified by negative book value, high leverage (debt ratio of 81.1%), and exposure to government reimbursement risk. The market is pricing in a normalization of earnings rather than a structural decline, as the 18.4% gap between trailing and forward P/E suggests expected EPS growth.
HCA is a reasonable buy for value-oriented investors with a medium-to-long-term horizon, but it is not a screaming bargain. The stock trades at a forward P/E of 13.31x, a 25-30% discount to the broader healthcare sector, and offers 5.7% upside to the average analyst target of $451.48. However, the downside risk is meaningful: the analyst low target of $380 implies 11.0% downside, and the 52-week low of $353.99 represents a 17.1% decline. The biggest risk is further reimbursement pressure, as evidenced by the 131 basis point sequential drop in operating margin to 14.98% in Q1 2026. For investors who believe policy headwinds are priced in, HCA offers a solid risk/reward, but those seeking high growth should look elsewhere.
HCA is better suited for long-term investment than short-term trading. The company is a mature, large-cap operator with a market cap of $107.7 billion, revenue growth of 4.3%, and a modest dividend yield of 0.63%. Its beta of 1.109 and max drawdown of -33.72% indicate that short-term price swings can be severe, especially around policy news and earnings. The stock's 5.19 short ratio and wide analyst target range of $380 to $579 suggest that near-term volatility will persist until reimbursement trends clarify. For long-term investors, the aging U.S. population and HCA's dominant scale provide a durable growth tailwind, and the forward P/E of 13.31x offers a reasonable entry point. A minimum holding period of 2-3 years is recommended to ride out policy cycles and allow buybacks to compound EPS.